Skip to main content
JAGX
NASDAQ Life Sciences

Jaguar Health Secures $350K in Short-Term Notes and Warrants for Working Capital

Analysis by Arik Shkolnikov
Sentiment info
Neutral
Importance info
7
Price
$0.888
Mkt Cap
$3.41M
52W Low
$0.855
52W High
$27
Market data snapshot near publication time

summarizeSummary

Jaguar Health, Inc. amended a previous 8-K to correct dates related to a $350,000 unsecured promissory note and warrants for 350,000 shares, with proceeds allocated for working capital.


check_boxKey Events

  • Secured Short-Term Financing

    Jaguar Health, Inc. entered into securities purchase agreements for $350,000 aggregate principal amount of unsecured promissory notes, maturing in one month.

  • Issued Warrants for Future Equity

    Investors also received warrants to purchase up to 350,000 shares of common stock at an exercise price of $1.00 per share, exercisable immediately.

  • Capital for Working Capital

    Proceeds from the notes will be used for working capital and general corporate purposes.

  • Amendment to Correct Dates

    This 8-K/A corrects scrivener's errors in the original filing regarding the execution and closing dates of the agreements, now confirmed as January 6, 2026.


auto_awesomeAnalysis

This amended 8-K clarifies the execution and closing dates of a recent financing agreement. The underlying transaction involves Jaguar Health securing $350,000 through unsecured promissory notes, which mature in a very short one-month period. Additionally, investors received warrants to purchase 350,000 shares at an exercise price of $1.00, a premium to the current stock price. While the capital infusion is crucial for working capital, the short maturity of the notes indicates immediate financial needs and could pose a refinancing challenge soon. The premium pricing of the warrants, however, suggests some investor confidence in the company's future value.

At the time of this filing, JAGX was trading at $0.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.4M. The 52-week trading range was $0.86 to $27.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed JAGX - Latest Insights

JAGX
May 08, 2026, 9:00 AM EDT
Source: Access Newswire
Importance Score:
7
JAGX
May 07, 2026, 2:59 PM EDT
Filing Type: 8-K
Importance Score:
8
JAGX
May 06, 2026, 9:00 AM EDT
Source: Access Newswire
Importance Score:
8
JAGX
May 04, 2026, 5:09 PM EDT
Filing Type: 8-K
Importance Score:
8
JAGX
May 04, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
9
JAGX
Apr 30, 2026, 9:57 AM EDT
Filing Type: DEF 14A
Importance Score:
9
JAGX
Apr 29, 2026, 8:30 AM EDT
Source: Access Newswire
Importance Score:
7
JAGX
Apr 27, 2026, 9:10 AM EDT
Filing Type: 8-K
Importance Score:
8
JAGX
Apr 27, 2026, 9:00 AM EDT
Source: Access Newswire
Importance Score:
8
JAGX
Apr 21, 2026, 8:22 AM EDT
Filing Type: PRE 14A
Importance Score:
10